MwanzoARCT • NASDAQ
add
Arcturus Therapeutics Holdings Inc
$ 12.91
Baada ya Saa za Kazi:(0.00%)0.00
$ 12.91
Imefungwa: 25 Apr, 16:02:36 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 12.89
Bei za siku
$ 12.29 - $ 12.98
Bei za mwaka
$ 8.04 - $ 44.99
Thamani ya kampuni katika soko
350.12M USD
Wastani wa hisa zilizouzwa
elfu 428.97
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Investor's Business Daily
dakika 13 zilizopita
What To Do Amid Tariffs, Earnings? Listen To The Market
0.050%
2.65%
0.44%
1.31%
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 22.77M | -26.22% |
Matumizi ya uendeshaji wa biashara | 12.38M | -1.02% |
Mapato halisi | -30.00M | -156.30% |
Kiwango cha faida halisi | -131.80 | -247.39% |
Mapato kwa kila hisa | -1.11 | -246.88% |
EBITDA | -32.58M | -86.60% |
Asilimia ya kodi ya mapato | 0.01% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 237.03M | -18.83% |
Jumla ya mali | 344.07M | -19.87% |
Jumla ya dhima | 103.09M | -31.68% |
Jumla ya hisa | 240.98M | — |
hisa zilizosalia | 27.12M | — |
Uwiano wa bei na thamani | 1.45 | — |
Faida inayotokana na mali | -23.36% | — |
Faida inayotokana mtaji | -29.77% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -30.00M | -156.30% |
Pesa kutokana na shughuli | elfu -284.00 | 54.85% |
Pesa kutokana na uwekezaji | 0.00 | 100.00% |
Pesa kutokana na ufadhili | elfu 134.00 | 100.72% |
Mabadiliko halisi ya pesa taslimu | elfu -150.00 | 99.26% |
Mtiririko huru wa pesa | 9.53M | 143.91% |
Kuhusu
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. As of 2021, vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2013
Tovuti
Wafanyakazi
175
